Teva Pharmaceuticals USA controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile4 entries
2022
U.S. opioid litigation settlements
Teva reached a nationwide framework and subsequent state agreements addressing claims by U.S. governmental entities concerning the marketing and distribution of opioids. The arrangements included monetary and in-kind commitments; Teva stated that the settlements did not admit wrongdoing.
2020
U.S. government sues Teva over alleged Copaxone kickbacks
Lawsuit filed
The U.S. Department of Justice sued Teva under the Federal False Claims Act. The lawsuit alleges that Teva companies used purportedly independent foundations to pay Medicare co-pays for Copaxone patients in violation of the Anti-Kickback Statute. The allegations are not presented as a court finding.
Source excerpt
The lawsuit claims that Teva paid two third-party foundations more than $300 million to cover Medicare co-payment obligations of Copaxone patients.
According to the lawsuit, Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. illegally paid the Medicare co-pays for their multiple sclerosis product, Copaxone, through purportedly independent foundations that the companies used as conduits in violation of the Anti-Kickback Statute.
Teva Pharmaceutical Industries Ltd. (TEVA) has been sued by the U.S. Department of Justice under the Federal False Claims Act.
2020
Astellas files patent-infringement complaint against pharmaceutical companies
Lawsuit filed
Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies, alleging that their proposed generic versions of Myrbetriq would infringe the '780 patent. The plaintiffs sought court relief; the allegations are claims in the complaint.
Source excerpt
At the District Court of Delaware on Tuesday, Astellas Pharma Inc. (API), Astellas Ireland Co. Ltd. (AICL), and Astellas Pharma Global Development (APGD) filed a complaint against 21 pharmaceutical companies alleging patent infringement.
The defendants are as follows: Sandoz Inc., Actavis Elizabeth LLC, Actavis LLC, Teva Pharmaceuticals USA Inc., Apotex Inc., Apotex Corp., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Sawai Pharmaceutical Co. Ltd., Sawai USA Inc., Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Huahai US Inc., Solco Healthcare US LLC, Windlas Healthcare Pvt. Ltd., Windlas Biotech Ltd., Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. (doing business as Zydus Cadila), Lupin Ltd., and Lupin Pharmaceuticals, Inc.
The patent in question, deemed the ’780 patent, corresponds to APGD’s Myrbetriq extended-release tablets, containing active ingredient mirabegron, which is used to treat overactive bladder.
2019
Virginia files opioid lawsuit against Teva Pharmaceuticals USA
Lawsuit filed
In 2019, Virginia Attorney General Mark Herring filed a lawsuit against Teva Pharmaceuticals USA and a company it had acquired. The lawsuit alleged that the companies misrepresented the benefits and risks of products including fentanyl. The filing was reported as part of litigation over opioids involving the state of Virginia and Teva Pharmaceuticals USA.
Source excerpt
Mark Herring filed a lawsuit Thursday against Teva Pharmaceuticals USA, saying it and a company that it bought misrepresented the benefits and risks of products that include fentanyl.